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Abstract
Purpose Endogenous Cushing’s syndrome (CS) is a rare
disease that results from exposure to high levels of cortisol;
Cushing’s disease (CD) is the most frequent form of CS.
Patients with CS suffer from a variety of comorbidities that
increase the risk of mortality. Surgical resection of the
disease-causing lesion is generally the first-line treatment
of CS. However, some patients may not be eligible for
surgery due to comorbidities, and approximately 25 % of
patients, especially those with CD, have recurrent disease.
For these patients, adrenal steroidogenesis inhibitors may
control cortisol elevation and subsequent symptomatology.
CS is rare overall, and clinical studies of adrenal
steroidogenesis inhibitors are often small and, in many
cases, data are limited regarding the efficacy and safety of
these treatments. Our aim was to better characterize the
profiles of efficacy and safety of currently available adrenal
steroidogenesis inhibitors, including drugs currently in
development.
Methods We performed a systematic review of the litera-
ture regarding adrenal steroidogenesis inhibitors, focusing
on novel drugs.
Results Currently available adrenal steroidogenesis inhi-
bitors, including ketoconazole, metyrapone, etomidate, and
mitotane, have variable efficacy and significant side
effects, and none are approved by the US Food and Drug
Administration for CS. Therefore, there is a clear need for
novel, prospectively studied agents that have greater effi-
cacy and a low rate of adverse side effects. Efficacy and
safety data of current and emerging adrenal steroidogenesis
inhibitors, including osilodrostat (LCI699) and levoketo-
conazole (COR-003), show promising results that will have
to be confirmed in larger-scale phase 3 studies (currently
ongoing).
Conclusions The management of CS, and particularly CD,
remains challenging. Adrenal steroidogenesis inhibitors
can be of major interest to control the hypercortisolism at
any time point, either before or after surgery, as discussed
in this review.
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Introduction
Cushing’s syndrome (CS) is a potentially fatal disease
associated with chronic hypercortisolemia [1]. Endogenous
CS is rare, with an annual estimated incidence of approx-
imately 0.7–2.4 cases per million people [1]. Patients with
CS have a mortality risk that is approximately 3.5–5 times
higher than the general population if not appropriately
treated [2]. The increased mortality with CS is, in part,
related to an increased risk of cardiovascular disease and
coagulation disorders [3–5]. The risk of myocardial
infarction is approximately 4.5 times higher, and the risk of
venous thromboembolism is approximately 20.6 times
higher in patients with CS compared with the general
population [2]. Elevated cortisol levels in patients with CS
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also result in a range of comorbidities, including cardio-
vascular (e.g., venous thrombosis, hypertension), derma-
tological (e.g., plethora, ecchymoses), metabolic (e.g.,
weight gain, abnormal glucose tolerance), reproductive
(e.g., decreased libido, menstrual changes), neuropsychi-
atric (e.g., lethargy, depression), and musculoskeletal (e.g.,
muscle weakness) symptoms [1].
Treatment options that directly address the hypercorti-
solemia include surgery (pituitary, adrenal, or ectopic
tumor resection), medical treatment, and/or radiotherapy
[6, 7]. Each option has its drawbacks; for instance, radia-
tion techniques become fully effective only after a pro-
longed period of time (3–5 years) and medical treatment,
as a bridge is necessary. Focusing more specifically on
Cushing’s disease (CD), the most frequent etiology of CS,
the 2015 Endocrine Society Clinical Practice Guideline
recommends surgical resection of the pituitary lesion as a
first line of treatment, unless surgery is contraindicated or
unlikely to successfully reduce excess cortisol levels [6].
For patients for whom disease was not controlled by initial
surgery, or for patients with severe, life-threatening dis-
ease, bilateral adrenalectomy is also an option [6]. How-
ever, as a result of the adrenal insufficiency (AI) induced
by bilateral adrenalectomy, patients undergoing the pro-
cedure will require hydrocortisone replacement and have
an increased risk of adrenal crises during their lifetime [8].
Medical treatment is recommended in patients who are
not surgical candidates, or for whom surgery has failed,
and in patients awaiting the effects of radiation therapy/
radiosurgery [6].
There are three specific targets for medical therapy in
CD, the corticotroph tumor, adrenal steroidogenesis inhi-
bitors, and glucocorticoid receptor blockers.
Steroidogenesis inhibitors are recommended by the
Endocrine Society as second-line treatment after ade-
nomectomy in CD, depending on clinical circumstances; as
first-line treatment for patients with ectopic adrenocorti-
cotropic hormone (ACTH) secretion when a tumor is not
detected; or as an adjunct treatment for patients with
adrenocortical carcinoma [6].
Corticotropin (ACTH) stimulates steroidogenesis by the
adrenal glands [9]. Through a variety of enzymatic reac-
tions, cholesterol, the common steroid precursor, is con-
verted to aldosterone, cortisol, or androstenedione (Fig. 1).
Adrenal steroidogenesis inhibitors, which act by blocking
various steps in the steroid biosynthesis pathway resulting
in reduced production of cortisol and other steroids, are a
cornerstone of medical treatment of CS [10]. This review
summarizes the key features of different adrenal steroido-
genesis inhibitors for the treatment of CS, with particular
emphasis on steroidogenesis inhibitors currently in clinical
development. Mechanisms of action, efficacy, and safety of
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the adrenal steroidogenesis inhibitors are discussed in
detail below and summarized in Table 1.
Adrenal steroidogenesis inhibitors currently
in clinical use
Ketoconazole
Ketoconazole, a synthetic imidazole derivative, is an
antifungal that, at higher doses (400–1200 mg), reduces
adrenal steroid production [11]. However, due to liver
toxicity, the approved use of ketoconazole in the United
States (US) is restricted to the treatment of serious fungal
infections with no other viable treatment options [7, 12].
Ketoconazole is approved for the treatment of CS in the
European Union [13]. While not approved for the treatment
of CS by the US Food and Drug Administration (FDA),
ketoconazole is one of the most commonly used steroido-
genesis inhibitors for off-label treatment of CS [11].
Ketoconazole inhibits key cytochrome P450 (CYP)
enzymes involved in multiple steps of steroidogenesis in
the adrenal cortex, including CYP17A1, CYP11A1,
CYP11B1, and CYP11B2 [10, 14, 15]. Ketoconazole is a
50/50 racemic mixture of 2S,4R and 2R,4S enantiomers
[16], and these enantiomers exhibit differences in inhibi-
tory potency for the enzymes involved in steroidogenesis
[17–19]. Ketoconazole has also been reported to directly
inhibit ACTH secretion [20], although these findings have
not been confirmed [21].
In patients with CS, ketoconazole treatment has been
associated with significant decreases in urinary free cortisol
(UFC) and urinary levels of cortisol and androgen
metabolites [22]. A retrospective study of 200 patients
Table 1 Mechanisms of action of steroidogenesis inhibitors [21]
Mechanism of action Efficacy
(%)
Common side effects
Ketoconazole Inhibitor of CYP17A1, CYP11A1, and CYP11B1 53–88 Liver enzyme increase
Gastrointestinal AEs
Interactions with multiple drugs
Not approved for use during pregnancy
Metyrapone Inhibitor of CYP11B1, CYP11B2, and CYP17A1 75 Hypokalemia
Hypertension
Gastrointestinal AEs
Hirsutism
Not approved for use during pregnancy
Etomidate Inhibitor of CYP11B1, CYP17A1, and CYP11A1 NR Hypnosis
Not approved for use during pregnancy
Mitotane Inhibitor of CYP11A1, CYP11B1, and CYP11B2 *70 Gastrointestinal AEs
Neurological side effects
Teratogen (not approved for use during
pregnancy)
Osilodrostat
(LCI699)
Inhibitor of CYP11B2 and CYP11B1 at higher doses 78–92 Nausea
Hirsutism
Fatigue
Headache
Hypokalemia
Not approved for use during pregnancy
Levoketoconazole
(COR-003)
Inhibitor of CYP17A1, CYP11A1, CYP11B1, and
CYP21A2
NR Headachea
Nauseaa
Mild liver enzyme increasea
Not approved for use during pregnancy
CYP, cytochrome P450; AE, adverse event; NR, not reported. All of these drugs can induce adrenal insufficiency
a In patients with diabetes mellitus
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receiving single-agent ketoconazole reported that 50 % of
the patients had normal UFC at the end of the study, while
26 % of ‘‘uncontrolled’’ patients had a C50 % decrease in
UFC; concurrent improvements in hypertension, diabetes,
and hypokalemia were also observed [23]. Escape from
ketoconazole-mediated control occurred in some patients
(7 %) [8]. However, interestingly, 50 % of the patients
treated for more than 24 months (mean = 108 months)
remained controlled with a stable dose of ketoconazole [23].
Elevations in liver enzymes occurred in approximately
15 % of patients treated with ketoconazole [23, 24]. Liver
enzyme levels returned to normal within 1–4 weeks after
lowering the dose or discontinuing treatment, and severe
drug-induced liver injury was rare [25]. In this retrospec-
tive analysis, no fatal hepatitis was observed; however, a
dramatic (*40-fold) increase in liver enzymes was
observed in one patient who was consuming concomitant
alcohol and high-dose acetaminophen [23]. Similarly, in
retrospective chart review, elevation of liver enzymes and
severe acute liver injury were rarely observed with keto-
conazole treatment [26].
Concomitant use of drugs with known hepatotoxic
effects should be avoided, and acid-lowering drugs should
be used with caution, as they decrease the efficacy of
ketoconazole [24]. Adrenal insufficiency is rare, except
when the treatment is given as a block-and-replace strategy
(a regimen in which cortisol production is completely
inhibited by steroidogenesis inhibitors and glucocorticoids
are administered to fulfill physiologic needs) [23]. Keto-
conazole may also affect gonadal testosterone synthesis,
resulting in decreased androgen levels and subsequent
hypogonadism and gynecomastia in male patients; there-
fore, it is generally used as a second-line medical therapy
in men (patients in whom metyrapone might be more
appropriate, from this point of view) [11, 25].
Metyrapone
Metyrapone is FDA approved for the diagnosis of AI in the
US [27] and is used clinically, off label, for the treatment of
CS [10]. In the European Union, metyrapone is approved for
the treatment of CS [13]. Metyrapone exhibits potent, rel-
atively selective inhibition of CYP11B1, but also inhibits
the activity of CYP11B2 [28]. Significant reductions in
urinary secretion of cortisol and aldosterone have been
observed with metyrapone treatment [29]. In a retrospective
study of 164 patients with CS who received metyrapone
monotherapy, 43–76 % of patients achieved control of
cortisol levels (defined by prespecified values of mean
serum cortisol day-curve, 24-hour UFC, and 09.00 h corti-
sol) [30]. No escape was reported, and 83 % of the patients
treated for more than 12 months (mean = 22 months) were
controlled on a stable dose of metyrapone [30].
Metyrapone has been associated with gastrointestinal
adverse events and hypoadrenalism [6, 30]. Despite the
accumulation of adrenogenic and mineralocorticoid pre-
cursors associated with metyrapone treatment, incidence of
metyrapone-related hirsutism, acne, and edema were rare,
albeit not prospectively studied, and hypokalemia was
reported but manageable with replacement [30]. Of note,
some patients were initially treated with antialdosterone
drugs, which might have led to an underestimation of
worsening of hypokalemia and hypertension. Although no
clear recommendation has been made on this specific point,
metyrapone is probably a better choice for a second-line
medical treatment in females for whom a long-term treat-
ment is necessary because of hyperandrogenism [6].
Etomidate
Etomidate, an imidazole derivative, is used for the induc-
tion of anesthesia and is also a potent and dose-dependent
inhibitor of CYP11B1, CYP17A1, and CYP11A1
[6, 21, 31, 32]. Etomidate can be administered intra-
venously and is often used for seriously ill patients with
severe hypercortisolemia who cannot take oral medication
[6, 21]. However, only a few cases of its use have been
reported in the literature.
Earlier studies demonstrated that inhibition of cortisol
was rapidly achieved with low-dose (2.5 mg/h) etomidate
in patients with hypercortisolism and was distinct from the
sedative effects of the drug [33]. In patients with CS,
etomidate treatment resulted in significant suppression of
serum cortisol levels within 11 h of infusion [34]. In an
emergency setting, patients with CS who received etomi-
date at a dose of 0.1 mg/kg per hour exhibited rapid and
prolonged suppression of serum cortisol levels [34]. The
most common side effects associated with etomidate were
hypnotic effect, reduced blood pressure, myoclonus, dys-
tonia, nausea, and vomiting [31, 33]. Adrenal insufficiency
has also been reported, which may require glucocorticoid
replacement [31], thus a block-and-replace protocol is used
in most cases. Etomidate is unstable in water, and is often
administered in a formulation containing propylene glycol,
which may increase the incidence of hemolysis and
nephrotoxicity [33].
Mitotane
Mitotane, a synthetic derivative of the pesticide
dichlorodiphenyltrichloroethane, is indicated for the treat-
ment of adrenocortical carcinoma, but in rare cases may be
used for the treatment of hypercortisolemia [10, 35].
Mitotane inhibits CYP11A1, CYP11B1, CYP11B2, and
5a-reductase [7, 10]. In patients with CS, mitotane treat-
ment has been associated with significant reductions in
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cortisol and androgen levels [36]. In the largest study (76
patients) reported to date on the use of mitotane in CD,
control of cortisol hypersecretion was observed in 72 % of
the patients after a median time of 6.7 months; the mito-
tane level necessary to obtain control was lower than the
level recommended for the treatment of adrenal carcinoma
(8.5 vs 14 lg/L, respectively). Interestingly, 75 % of the
patients needed to be treated with hydrocortisone in par-
allel, probably due to adrenal atrophy, but this effect was
transient in the majority of the patients, as withdrawal of
the drug led to recurrence in 71 % of them [37]. Results
were similar in patients treated for ectopic ACTH secre-
tion; 21/23 patients (91 %) achieved normal UFC levels
after a mean time of 4.5 months [38].
Mitotane is associated with a number of potential side
effects, including hypercholesterolemia, anorexia, gas-
trointestinal symptoms, decreased memory and other neu-
rological side effects, and abnormal liver function [31, 38];
these side effects lead to discontinuation of treatment in
approximately a quarter of patients and require close
monitoring of plasma mitotane levels [6]. A recent study of
premenopausal women demonstrated a high incidence of
menstrual disorders and ovarian macrocysts in women
receiving mitotane, which may be related to elevated levels
of luteinizing hormone, follicle-stimulating hormone, and
estrogen as a consequence of mitotane alleviating the
negative feedback normally exerted by the ovaries on the
production of those hormones [39].
Adrenal steroidogenesis inhibitors in clinical
development
Osilodrostat (LCI699)
Osilodrostat is a potent and relatively selective inhibitor of
CYP11B2 that also inhibits CYP11B1 at higher doses [40].
In comparison to metyrapone, which also inhibits
CYP11B1, osilodrostat is a more potent inhibitor of
CYP11B1 (IC50 2.5 vs 7.5 nM) and has a longer half-life
(4–5 vs 2 h) [41]. Osilodrostat was initially developed as a
possible treatment option for hypertension, cardiac failure,
and renal disease [10]. In studies in patients with hyper-
tension, significant and dose-dependent decreases in urine
and plasma levels of aldosterone and a blunting of the
cortisol response to synthetic ACTH were observed [10].
In a 10-week, proof-of-concept study in patients with
CD (n = 12) who had previously undergone pituitary
surgery and had UFC greater than 1.5 times the upper limit
of normal (ULN), 92 % of patients achieved normalization
of UFC within 10 weeks of initiating osilodrostat treat-
ment, with all patients achieving C50 % decreases in UFC
levels from baseline [42]. After treatment discontinuation,
UFC levels rose above the ULN [42]. In a longer term,
22-week, phase 2 study of osilodrostat in patients with CD
with UFC levels above the ULN, normalization of cortisol
levels was achieved in 84 % of patients by week 10 and
79 % by the end of the study [41]. In both studies, patients
achieved normal UFC within a month of starting treatment
[41, 42]. Plasma levels of cortisol and aldosterone were
decreased in both studies, while levels of their precursors,
11-deoxycortisol and 11-deoxycorticosterone, increased
[41, 42]. Although blood pressure decreased from baseline
in the proof-of-concept study, data from the phase 2 study
showed no changes in blood pressure [41, 42].
In patients with CD, osilodrostat is also associated with
an increase in ACTH (3- to 4-fold), which, due to the
subsequent increase in 11-deoxycorticosterone, may be
associated with the development of certain side effects
(worsening of hypokalemia, increased blood pressure
levels) [10]. These side effects were not specifically
reported in the studies previously described. Adrenal
insufficiency was observed in approximately 32 % of
patients in the phase 2 study [41]. The most common
adverse events in both studies were gastrointestinal adverse
events (e.g., nausea, diarrhea); adverse events associated
with adrenal insufficiency (i.e., fatigue, dizziness, nausea,
muscle spasms, hypotension, and syncope) led to dose
reductions of osilodrostat [41, 42]. In both studies,
increased levels of testosterone were observed in female
patients [41, 42], and in the phase 2 study, symptoms of
hirsutism occurred in a third of the female patients who
completed the study [41].
A phase 3, double-blind, randomized withdrawal study
(ClinicalTrials.gov identifier NCT02180217) of osilo-
drostat in patients with persistent, recurrent CD or
untreated CD who are not candidates for surgery is ongoing
(estimated enrollment = 132) [43]. Patients receive osilo-
drostat during a 12-week, open-label, dose-titration period
(weeks 1–12), followed by a 12-week, open-label,
stable treatment period (weeks 13–24); then patients are
randomized to receive osilodrostat or a placebo during an
8-week double-blind period (weeks 26–34), and, finally, all
patients receive open-label osilodrostat from weeks 35 to
48. The primary endpoint is the proportion of patients with
normal mean UFC values per treatment group at 34 weeks.
Levoketoconazole (COR-003)
Levoketoconazole is the 2S,4R enantiomer of ketocona-
zole, purified from racemic ketoconazole [44]. In early
in vitro analyses, levoketoconazole was shown to be a more
potent inhibitor than the 2R,4S enantiomer of several
enzymes in the steroidogenic pathway, including
CYP11B1, a key enzyme in the final step of adrenal cor-
tisol synthesis; levoketoconazole had a half maximal
Pituitary (2016) 19:643–653 647
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inhibitory concentration for CYP11B1 that was approxi-
mately 4 times lower than the 2R,4S enantiomer [17–19].
As an azole antifungal, levoketoconazole was screened as
an inhibitor of a critical enzyme for fungal survival,
CYP51A1, which also happens to be a key enzyme in
cholesterol synthesis. Levoketoconazole was shown to be a
more potent inhibitor of CYP51A1 than the 2R,4S enan-
tiomer [19]. Results of more recent analyses of the effects
of racemic ketoconazole, levoketoconazole, and 2R,4S-
ketoconazole on steroidogenic CYP enzymes support those
of early in vitro studies [45]. In those analyses, levoketo-
conazole showed more potent inhibition of CYP17A1,
CYP21A2, and CYP11B1 than either racemic ketocona-
zole or 2R,4S-ketoconazole [45]. Thus, a lower dose of
levoketoconazole may potentially be used to achieve the
same clinical effects as racemic ketoconazole; however,
controlled clinical trials of different doses of levoketo-
conazole compared with racemic ketoconazole are needed
to support these findings. In preclinical studies in rats,
levoketoconazole had a greater potency for decreasing
corticosterone (the main glucocorticoid in rats [46]) and
testosterone levels than the 2R,4S enantiomer or racemic
ketoconazole [45]. Levoketoconazole-mediated decreases
in corticosterone were dose-dependent. Levoketoconazole
treatment has not yet been evaluated in patients with CS;
however, clinical results in healthy subjects and patients
with type 2 diabetes support preclinical results showing
suppression of corticosterone by levoketoconazole. In an
analysis of cortisol levels over time in healthy subjects, the
mean area under the curve (AUC) for cortisol was lower
following administration of both levoketoconazole and
ketoconazole compared with placebo. In a study in patients
with type 2 diabetes, nonsignificant mean reductions in
12-hour overnight plasma cortisol AUC were observed
with both ketoconazole and levoketoconazole after 14 days
of dosing [47]. Interestingly, no dose-dependent trend in
the percentage change in testosterone was found with
levoketoconazole administration [47]. Finally, significant
decreases in low-density lipoprotein cholesterol levels
were observed in diabetic patients treated with levoketo-
conazole [47]. Levoketoconazole treatment also resulted in
nonsignificant lower serum cholesterol levels in rats than
the 2R,4S enantiomer or racemic ketoconazole. This may
be of particular clinical relevance for patients with CS who
have a substantially increased risk of cardiovascular events
[2].
In patients with type 2 diabetes, headache and nausea
were the most commonly reported adverse events [47].
Although levoketoconazole treatment has not yet been
evaluated in patients with CS, levoketoconazole may have
a more favorable safety profile than racemic ketoconazole,
which has been associated with clinically relevant drug–
drug interactions and hepatotoxicity. The pharmacokinetic
profiles of levoketoconazole and the 2R,4S enantiomer
suggest preferred extraction of the 2R,4S enantiomer by the
liver, which may indicate a lower risk of hepatotoxicity
with levoketoconazole [45]. In addition, levoketoconazole
shows less potent inhibition of CYP7A1, a rate-limiting
enzyme in bile acid synthesis, than the 2R,4S enantiomer
[47]. Nevertheless, there has been some clinical evidence
of alterations in liver function enzymes with levoketo-
conazole treatment [47, 48]; further studies will be needed
to clarify whether decreased hepatotoxicity is observed
with levoketoconazole in patients with CS. A single-arm,
open-label, dose-titration study evaluating levoketocona-
zole in patients with persistent or recurrent CS, or newly
diagnosed patients who are not candidates for surgery, is
ongoing (ClinicalTrials.gov identifier NCT01838551) [44].
The study has a variable dose-titration phase, a 6-month
maintenance phase in which patients receive levoketo-
conazole at the therapeutic dose, and a 6-month extended
evaluation phase. The primary endpoint is the rate of
normalized 24-hour UFC at 6 months of maintenance
without dose increase; safety issues are closely monitored
in this study.
Clinical considerations for treatment with adrenal
steroidogenesis inhibitors in CS
Drug interactions
Most adrenal steroidogenesis inhibitors have the potential
for drug interactions with drugs metabolized by CYP
enzymes (Table 2). Both mitotane and ketoconazole are
strong inhibitors of CYP3A4 and may enhance the activity
of drugs metabolized by CYP3A4, including oral antico-
agulants, statins, cyclosporine, and tacrolimus [49–51]. The
inhibitory effects of mitotane treatment on CYP3A4 are
long lasting and have been observed several months after
therapy is discontinued [51]. Levoketoconazole has similar
effects to those of racemic ketoconazole on the CYP
enzymes most relevant to drug metabolism [45]. Like
ketoconazole, levoketoconazole has the potential for drug
interactions with drugs metabolized via CYP3A4 (e.g.,
felodipine and atorvastatin) [45]. In drug interaction stud-
ies, exposure of felodipine was increased 10-fold with
coadministration of levoketoconazole, while exposure to
atorvastatin was increased by *30 % when coadminis-
tered with levoketoconazole (compared with a *50 %
increase with coadministration of racemic ketoconazole).
In vitro data have also indicated that ketoconazole inhibits
the cardiac potassium channel, hERG, which may result in
prolongation of QT interval; thus, ketoconazole should be
used with caution when used in combination with agents
that also prolong QT interval or are metabolized by
648 Pituitary (2016) 19:643–653
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CYP3A4 [52]. In studies of healthy subjects, ketoconazole
significantly increased QT interval [53, 54]. A trend toward
prolongation of QT interval was also reported in a study of
levoketoconazole in healthy subjects [45]. While it is likely
that the effect of levoketoconazole on QT interval will be
similar to that of ketoconazole, additional studies are
needed. Mifepristone, a glucocorticoid receptor antagonist,
is also metabolized by CYP3A; thus, drugs that inhibit
CYP3A, such as ketoconazole and levoketoconazole, may
increase plasma mifepristone concentrations [55]. Coad-
ministration of these drugs is rare; however, it is important
to ensure an adequate wash-out when switching from one
therapy to another.
Combination therapy
Steroidogenic inhibitors are typically administered as
monotherapy [6]. Combination therapy may be necessary
in patients who do not respond to monotherapy or who
experience dose-limiting side effects [10]. In patients with
severe CS, combining more than two adrenal steroidoge-
nesis inhibitors has also been shown to be effective.
Combination therapy with ketoconazole and cabergoline
normalized UFC in 79 % of patients with CD; however,
based on late-night salivary cortisol levels, subclinical
hypercortisolism persisted in patients treated with this
combination [56]. In a study of 17 patients with CD,
treatment with a regimen of pasireotide, cabergoline, and
ketoconazole normalized UFC levels in 88 % of patients
by day 80; reductions in UFC levels of up to 67 % were
observed in patients with mild (1 to \2 times ULN) or
severe (4–6 times ULN) CD [57]. Combination therapy
with ketoconazole and metyrapone is relatively common,
but is generally only considered for patients with more
severe disease or for those who have failed to respond to
monotherapy with either agent [10, 30]. Due to the rela-
tively slow onset of action of mitotane, combination ther-
apy with a rapid-onset steroidogenesis inhibitor may be
used during the first several months of treatment [10]. In
patients with severe hypercortisolism (UFC[5 times ULN)
related to ectopic ACTH syndrome or adrenal carcinoma,
the combination of metyrapone and ketoconazole (and in
some patients, subsequent mitotane) resulted in normal
UFC values in 73 % of patients (n = 22) and a concomi-
tant improvement of clinical symptoms, including hypo-
kalemia, hypertension, and diabetes [58]. Similarly, in a
study of 11 patients with severe hypercortisolism and sig-
nificant comorbidities that precluded surgical intervention,
who were administered metyrapone and ketoconazole fol-
lowed by mitotane maintenance therapy, UFC was nor-
malized in all patients receiving combination therapy and
remained below the ULN on maintenance therapy; all
patients were able to undergo surgery 5–22 months after
beginning combination therapy [59].
In mice, the combination of osilodrostat and pasireotide
was similar to the toxicity of either agent alone and
appeared to ameliorate the cellular hypertrophy associated
with osilodrostat therapy and the decrease in liver weight
Table 2 Drug–drug interactions with adrenal steroidogenesis inhibitors
Medical intervention Interacts with Potential for adverse event
Ketoconazole [24, 54, 69] CYP3A4 Drug–drug interactions with oral anticoagulants, statins, cyclosporine, and
tacrolimus
hERG Possible QT prolongation
Use acid-lowering and hepatotoxic drugs with caution
Metyrapone [68] UGT1 Drug–drug interactions occur frequently
Acetaminophen toxicity
Etomidate [70–73] CYP11B1 Etomidate should be given carefully with calcium channel blockers, opioids,
and benzodiazepines
Mitotane [35] CYP3A4 Drug–drug interactions with oral anticoagulants, statins, cyclosporine, and
tacrolimus
Hydrocortisone dose increased
Osilodrostat (LCI699)
[21, 60, 74]
CYP1A2 and CYP2C19 (moderate
inhibition)
CYP2D6 and CYP3A4 (weakly
inhibited)
Drug–drug interactions
Possible QT prolongation
Levoketoconazole
(COR-003) [21]
CYP3A4, CYP3A5
hERG
Drug–drug interactions with oral anticoagulants, statins, cyclosporine, and
tacrolimus
QT prolongation
CYP, cytochrome P450; hERG, human ether-a-go–go–related gene; UGT1, UDP-glucuronosyltransferase 1 family; NR, not reported
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following pasireotide therapy [60]. Additional studies are
needed in patients with CD to confirm these results.
Combination therapy with levoketoconazole has not yet
been evaluated in patients with CS; however, based on the
in vitro data, it is hypothesized that the greater potency of
levoketoconazole for cortisol suppression relative to keto-
conazole, along with its potentially favorable hepatic tol-
erability profile, may make levoketoconazole a better
option for combination therapy.
Preoperative treatment
The goal of presurgical medical treatment is to decrease the
comorbidities at the time of surgery and improve postop-
erative outcomes. Preoperative treatment could thus be of
particular interest in patients with comorbidities that are
difficult to manage with classical antihypertensive or
antidiabetic treatments. Results of preoperative therapy
with adrenal steroidogenesis inhibitors have not been
conclusive because some patients were only evaluated
based upon the rate of normal UFC obtained before surgery
and not on the rate of improvement of comorbidities [61].
In a retrospective study of 16 patients who received ade-
quate presurgical cortisol suppression therapy with keto-
conazole or metyrapone prior to undergoing
transsphenoidal surgery, postoperative cortisol suppression
was observed and, surprisingly, long-term remission was
significantly increased compared with patients with bor-
derline or inadequate cortisol suppression pretreatment
[62]. However, a retrospective study of previously
untreated patients who had a mean baseline UFC level of
793 nmol/24 h (approximately 3 times ULN) and who
were treated with steroidogenic inhibitors prior to surgery
found that preoperative treatment with ketoconazole and/or
metyrapone yielded normal UFC levels in approximately
50 % of patients, but normalization of UFC did not nec-
essarily lead to clinical benefit [61]. Further studies with
more well-defined patient inclusion criteria will be required
to clarify the role of presurgical treatment. Moreover, the
duration of this presurgical treatment is also controversial.
Taking into account the time needed to recover from
comorbidities, for instance after bilateral adrenalectomy,
would argue for the need for a prolonged presurgical
medical treatment [63].
Subclinical adrenal CS
Though controversial, subclinical CS or mild adrenal
hypercortisolism is defined as a subtle hypersecretion of
cortisol that does not fully manifest in a clinical phenotype
[64]. However, subclinical CS may be associated with an
increased risk of comorbidities, such as hypertension, type
2 diabetes, osteoporosis, dyslipidemia, or coronary heart
disease as a result of chronic cortisol elevation, but this
association has not been conclusively demonstrated. As a
result of the sparse data around treatment of subclinical CS,
treatment guidelines for subclinical CS vary [65]. Some
guidelines recommend adrenalectomy, particularly for
patients with worsening comorbidities, while others advo-
cate for careful monitoring of the patient [6, 66, 67]. While
the optimal treatment for these patients is not clear,
steroidogenic inhibitors are not currently recommended for
the treatment of subclinical CS. Thus, there is a clear need
for more studies evaluating the best course of treatment for
these patients. For instance, administering steroidogenesis
inhibitors as a first-line treatment might obviate the need
for adrenalectomy in patients who have bilateral adrenal
disease, have contraindications, or refuse surgery, if their
comorbidities are improved with the medical treatment.
Conclusions
CS has higher morbidity and mortality rates if not appro-
priately treated. Surgery is the first line of treatment, but
many patients do not achieve remission or experience
disease recurrence following surgery. Adrenal steroidoge-
nesis inhibitors are associated with high rates of cortisol
normalization and clinical improvements. Combination
therapies of well-studied drugs might allow for lower doses
with better tolerability. However, data from CS studies is
limited and there is a need for prospective studies of
adrenal steroidogenesis inhibitors with long-term follow-
up. In addition, agents with improved tolerability and
potency are needed. In phase 2 studies, osilodrostat pro-
vided cortisol normalization in almost 80 % of patients
with no short-term escape. Based on preclinical and early
clinical data in patients with diabetes, levoketoconazole
may be associated with a number of potential benefits
relative to steroidogenesis inhibitors currently in clinical
use. Both drugs are currently being evaluated in ongoing
phase 3 studies. Treatments that are tailored to each indi-
vidual patient’s needs are desirable; thus, expanded options
for medical treatment could lead to improved overall out-
comes for CS patients.
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